摘要
目的分析CalliSpheres载药微球经药物洗脱支气管动脉化疗栓塞术(drug-eluting beads bronchial arterial chemoembolization,DEB-BACE)治疗Ⅲ~Ⅳ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法回顾性选择2019年5月至2024年10月我院收治的23例DEB-BACE治疗Ⅲ~Ⅳ期NSCLC患者为观察组,23例传统BACE(conventional BACE,C-BACE)治疗Ⅲ~Ⅳ期NSCLC患者为对照组。比较两组治疗前后临床疗效和生活质量。结果BACE治疗后部分缓解(partial response,PR)18例,疾病稳定(stable disease,SD)23例。观察组客观缓解率(objective response rate,ORR)56.52%高于对照组21.74%(P=0.016)。BACE治疗期无3级及以上不良反应病例,1至2级不良反应23例(50.00%),其中观察组不良反应7例(30.43%)低于对照组16例(69.57%)(P<0.05)。观察组治疗后躯体功能(F_(时间)=14.497)、角色功能(F_(时间)=6.696)、认知功能(F_(时间)=4.839)和便秘症状(F_(时间)=22.000)改善(P<0.05);观察组治疗后生活质量(F_(组别)=10.863)、呼吸困难(F_(组别)=19.101)、食欲不振(F_(组别)=9.134)、腹泻(F_(组别)=22.000)改善优于对照组(P<0.05),咯血症状得到有效控制。随访中位数6.22个月,46例中存活者31例(67.39%)、死亡者15例(32.61%),其中观察组死亡者5例(21.75%),对照组死亡者10例(43.48%),Kaplan-Meier曲线显示,两组中位总生存期差异无统计学意义(P=0.181)。结论CalliSpheres DEB-BACE治疗Ⅲ~Ⅳ期NSCLC安全性和有效性好,有助于改善患者生活质量,CalliSpheres DEB-BACE是Ⅲ~Ⅳ期NSCLC患者治疗的替代选择。
Objective To analyze the clinical efficacy of CalliSpheres drug-eluting beads bronchial arterial chemoembolization(DEB-BACE)in the treatment of stage Ⅲ~Ⅳ non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on 23 stage Ⅲ~Ⅳ NSCLC patients treated with DEB-BACE(observation group)and 23 patients treated with conventional BACE(C-BACE,control group)at our hospital from May 2019 to October 2024.Clinical efficacy and quality of life were compared between the two groups before and after treatment.Results After BACE treatment,partial response(PR)was observed in 18 cases and stable disease(SD)in 23 cases.The objective response rate(ORR)in the observation group 56.52%was higher than that in the control group 21.74%(P=0.016).No grade 3 or higher adverse reactions occurred during BACE treatment,while 23 cases(50.00%)experienced grade 1-2 adverse reactions.The adverse reactions of 7 cases(30.43%)in the observation group was lower than 16 cases(69.57%)in the control group(P<0.05).In the observation group,significant improvements were observed in physical function(F_(time)=14.497),role function(F_(time)=6.696),cognitive function(F_(time)=4.839),and constipation symptoms(F_(time)=22.000)after treatment(P<0.05).Additionally,quality of life(F_(group)=10.863),dyspnea(F_(group)=19.101),loss of appetite(F_(group)=9.134),and diarrhea(F_(group)=22.000)showed greater improvement in the observation group compared to the control group(P<0.05),with hemoptysis symptoms effectively controlled.During a median follow-up of 6.22 months(0.47~20.80 months),31 patients(67.39%)survived and 15(32.61%)died,including 5 deaths(21.75%)in the observation group and 10 deaths(43.48%)in the control group.Kaplan-Meier curves indicated no statistically significant difference in median overall survival between the two groups(P=0.181).Conclusion CalliSpheres DEB-BACE demonstrates favorable safety and efficacy in treating stage Ⅲ~Ⅳ NSCLC,contributes to improved quality of life,and serves as a valuable alternative option for patients with stage Ⅲ~Ⅳ NSCLC.
作者
郑文涛
肖静
欧阳兵
吴毅
廖开友
李春林
Zheng Wentao;Xiao Jing;Ouyang Bing;Wu Yi;Liao Kaiyou;Li Chunlin(Department of interventional and vascular surgery,Chongqing University Affiliated Cancer Hospital,chongqing 400000,China)
出处
《中华肺部疾病杂志(电子版)》
2025年第5期691-696,共6页
Chinese Journal of Lung Diseases(Electronic Edition)
基金
2022年度重庆市医药生物技术协会科研育苗项目(cmba2022kyym-zkxmQ0010)。
